List of Excipients in Branded Drug NUTRILIPID I.V. FAT EMULSION

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
B Braun Medical Inc	NUTRILIPID I.V. FAT EMULSION	soybean oil	0264-4460	EGG PHOSPHOLIPIDS
B Braun Medical Inc	NUTRILIPID I.V. FAT EMULSION	soybean oil	0264-4460	GLYCERIN
B Braun Medical Inc	NUTRILIPID I.V. FAT EMULSION	soybean oil	0264-4460	SODIUM HYDROXIDE
B Braun Medical Inc	NUTRILIPID I.V. FAT EMULSION	soybean oil	0264-4460	SODIUM OLEATE
B Braun Medical Inc	NUTRILIPID I.V. FAT EMULSION	soybean oil	0264-4460	WATER

NUTRILIPID I.V. Fat Emulsion Excipient Strategy and Commercial Opportunities

Last updated: September 5, 2026

NUTRILIPID I.V. Fat Emulsion is a soybean-oil-based intravenous lipid emulsion used as a calorie source and for essential fatty-acid supplementation in parenteral nutrition. Its commercial position depends less on the active lipid ingredient than on excipient control, emulsion stability, container compatibility, sterility assurance, supply reliability, and clinical differentiation against mixed-oil and fish-oil emulsions.

The core formulation uses soybean oil, egg phospholipids, glycerin, sodium hydroxide, and water for injection. The most credible commercial opportunities are in excipient substitution, lower-inflammatory lipid systems, preservative-free nutrition products, specialty neonatal and critical-care formulations, ready-to-administer bags, and regional manufacturing partnerships.

What is NUTRILIPID I.V. Fat Emulsion?

NUTRILIPID is an intravenous fat emulsion manufactured by Fresenius Kabi USA, LLC. The product is used in adults and pediatric patients as a source of calories and essential fatty acids when oral or enteral nutrition is inadequate or contraindicated.[1]

The marketed formulation is a sterile oil-in-water emulsion containing soybean oil as the lipid phase. The commonly marketed concentration is 20%, equivalent to 20 grams of soybean oil per 100 mL of emulsion. The product is administered intravenously, generally as part of parenteral nutrition.

Attribute	NUTRILIPID I.V. Fat Emulsion
Manufacturer	Fresenius Kabi USA, LLC
Dosage form	Sterile intravenous oil-in-water emulsion
Primary lipid source	Soybean oil
Common concentration	20%
Primary clinical role	Calories and essential fatty acids in parenteral nutrition
Key emulsifier	Egg phospholipids
Other functional excipients	Glycerin, sodium hydroxide, water for injection
Route	Intravenous infusion
Main customer groups	Hospitals, nutrition-support teams, intensive-care units, pediatric centers
Principal competitors	Intralipid, SMOFlipid, Clinolipid, Omegaven

The formulation is not interchangeable with every lipid emulsion. Differences in oil composition, phospholipid content, osmolality, dosing, indications, and clinical data affect purchasing decisions and formulary placement.

What excipients are used in NUTRILIPID?

The principal excipients perform distinct formulation functions.

Component	Function in the formulation	Commercial and regulatory relevance
Soybean oil	Provides calories and essential fatty acids; forms the dispersed lipid phase	Commodity exposure, oxidation risk, allergen labeling, and agricultural supply variability
Egg phospholipids	Emulsifies soybean oil in water and stabilizes oil droplets	Egg allergy restrictions, source qualification, phospholipid purity, and interfacial stability
Glycerin	Adjusts tonicity and contributes to osmotic balance	Concentration control, compatibility, and injectable-grade supply
Sodium hydroxide	Adjusts pH	Low use level but relevant to pH stability and container compatibility
Water for injection	Continuous aqueous phase	Sterility, endotoxin control, and microbial-risk management

The label identifies soybean oil and egg phospholipids as major formulation components and warns against use in patients with known hypersensitivity to egg or soybean proteins.[1]

Why egg phospholipids matter

Egg phospholipids are not a passive excipient. They determine interfacial film formation around the oil droplets and influence emulsion stability during storage, transport, dilution, and infusion.

Commercial risks include:

• Batch-to-batch variability in phospholipid composition.
• Residual protein and allergen-control requirements.
• Oxidative degradation of phospholipid components.
• Supply dependence on specialized injectable-grade material.
• Compatibility limits when the emulsion is mixed with amino acids, dextrose, electrolytes, trace elements, or vitamins.

A credible excipient-development program would focus on alternative phospholipid systems, including highly purified egg phospholipids, synthetic phospholipids, or combinations of phosphatidylcholine and related amphiphiles. Any substitute would require comparative droplet-size analysis, zeta potential testing, peroxide and anisidine measurements, sterility studies, and clinical bridging.

Why glycerin matters

Glycerin supports isotonicity and helps control the product’s osmotic profile. It also affects viscosity and infusion behavior. Replacing or materially changing glycerin concentration could alter:

• Osmolality.
• Infusion tolerability.
• Compatibility with compounded parenteral nutrition.
• Container interaction.
• Stability during freeze-thaw or temperature excursions.

A lower-cost replacement would have limited value unless it preserved the product’s safety and compounding profile. Glycerin is widely available, so its strongest commercial role is as a benchmark excipient rather than a major differentiation point.

What formulation patents protect NUTRILIPID?

Publicly available FDA product information identifies the formulation and manufacturer, but NUTRILIPID’s commercial protection is not primarily associated with a prominent Orange Book patent exclusivity position. FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations should be reviewed for current patent and exclusivity listings associated with the relevant application and strength.[2]

For an injectable lipid emulsion, the most relevant intellectual-property categories are:

1. Composition claims covering the oil phase and emulsifier system.
2. Droplet-size distribution and emulsion-stability claims.
3. Manufacturing processes, including high-pressure homogenization.
4. Sterilization and aseptic-processing methods.
5. Container and closure systems.
6. Compounding compatibility with amino acids and dextrose.
7. Methods of reducing oxidation or maintaining physical stability.
8. Specialized formulations for neonatal, hepatic, or critical-care use.

A follow-on applicant would generally face a greater technical and regulatory burden than a conventional oral generic. Injectable emulsions require control of globule-size distribution, large-droplet tail, pH, osmolality, sterility, bacterial endotoxins, particulate matter, and preservative status.

Is NUTRILIPID listed in the Orange Book?

NUTRILIPID is an FDA-approved prescription injectable product, but the practical commercial question is whether a current listed patent or regulatory exclusivity period blocks an abbreviated new drug application. For mature parenteral nutrition products, market entry is more often constrained by formulation complexity, manufacturing capability, injectable-equivalence requirements, and hospital contracting than by long-lived composition patents.

FDA Orange Book data should be checked by application number, dosage form, and strength because listings can differ by product presentation.[2] A definitive freedom-to-operate opinion requires a current patent-family search across the United States, Europe, Canada, Japan, China, and major manufacturing jurisdictions.

When does NUTRILIPID lose exclusivity?

NUTRILIPID is a mature product, and its principal market barriers are likely technical and commercial rather than new chemical entity exclusivity. FDA approval does not itself establish a current period of market exclusivity for the product.

Exclusivity or barrier	Relevance to NUTRILIPID
New chemical entity exclusivity	Not the main protection for a mature soybean-oil emulsion
Orphan-drug exclusivity	Not the product’s principal commercial framework
Pediatric exclusivity	Must be verified in current FDA records
Listed patents	Must be checked in the current Orange Book
Injectable formulation complexity	High practical barrier
Hospital contracting	Significant commercial barrier
Supply-chain qualification	Significant barrier for new entrants
Sterile manufacturing capacity	High capital and compliance barrier

Generic launch risk should therefore be modeled around ANDA approval, product quality, supply continuity, and contracting rather than a simple patent-expiration date.

What generic entry risks exist for NUTRILIPID?

A generic or follow-on competitor would need to demonstrate pharmaceutical equivalence and bioequivalence or an appropriate scientific basis for an injectable emulsion. The technical development package would likely include:

• Quantitative and qualitative composition.
• Mean droplet diameter.
• Percentage of large-diameter lipid globules.
• Particle-size distribution over shelf life.
• pH and osmolality.
• Viscosity.
• Zeta potential or equivalent interfacial characterization.
• Peroxide and other oxidation markers.
• Sterility and bacterial endotoxin control.
• Container-closure integrity.
• Extractables and leachables.
• Compatibility with common parenteral nutrition admixtures.
• Stability after activation, dilution, and simulated infusion.

The most material launch risks are:

1. Failure to match physical stability.
2. Excessive large-droplet formation during storage.
3. Oxidation caused by oxygen ingress or light exposure.
4. Incompatibility with compounders’ standard workflows.
5. Shorter dating period than the reference product.
6. Inadequate supply of injectable-grade phospholipids.
7. Hospital reluctance to switch from a qualified supplier.

A competitor that matches composition but fails to match handling characteristics may have limited formulary value.

What excipient strategies could improve NUTRILIPID?

Oxidation-control strategy

Soybean oil contains polyunsaturated fatty acids that are vulnerable to oxidation. Commercial opportunities include:

• Lower-oxygen headspace packaging.
• Improved barrier films.
• Light-protective overwraps.
• Oxygen-scavenging secondary packaging.
• Tighter peroxide specifications for raw materials.
• Antioxidant systems that are acceptable for parenteral use.
• Improved control of metal-ion contamination.

The regulatory challenge is that any new antioxidant or oxygen-control material must be evaluated for safety, extractables, leachables, and product stability. Packaging improvements may offer a faster path than adding a new chemical excipient.

Alternative emulsifier strategy

Synthetic or highly purified phospholipid systems could reduce dependence on animal-derived egg material. Potential benefits include:

• More consistent composition.
• Lower residual-protein risk.
• Improved supply predictability.
• Greater control over interfacial properties.
• Potentially broader use in patients with egg hypersensitivity, subject to clinical and labeling support.

This strategy would require a robust equivalence package. A change in phospholipid source can modify droplet size, clearance, immune response, and compatibility with other parenteral nutrition components.

Mixed-oil strategy

A soybean-oil-only product can be repositioned through a next-generation mixed-oil platform containing combinations such as soybean oil, medium-chain triglycerides, olive oil, or fish oil. Such products can target concerns about omega-6 fatty-acid exposure and inflammatory lipid mediators.

This strategy would create a new product rather than a simple reformulation. It would need clinical evidence, a new regulatory pathway or supplemental approval, and a clear differentiation claim.

Existing products illustrate the opportunity:

Product	Lipid strategy	Commercial positioning
NUTRILIPID	Soybean oil	Established general parenteral nutrition lipid
Intralipid	Soybean oil	Long-established soybean-oil reference product
SMOFlipid	Soybean oil, MCT, olive oil, fish oil	Mixed-oil formulation with broader fatty-acid profile
Clinolipid	Olive oil and soybean oil	Reduced soybean-oil exposure relative to soybean-only products
Omegaven	Fish oil	Specialized fish-oil product, including parenteral-nutrition-associated cholestasis applications

FDA labeling and clinical positioning differ across these products.[1,3-6]

What commercial opportunities exist for NUTRILIPID?

Hospital and home-infusion supply

The largest opportunity is reliable supply to acute-care hospitals, long-term acute-care facilities, pediatric hospitals, and home-infusion providers. Buyers prioritize:

• Contract price.
• Product availability.
• Multiple bag sizes.
• Shortage resilience.
• Compatibility with automated compounding systems.
• Consistent dating.
• Low waste.
• Vendor qualification status.

A supplier that offers the same clinical role with stronger availability can gain share even without a new formulation.

Ready-to-administer nutrition systems

NUTRILIPID can be integrated into standardized parenteral nutrition programs using preconfigured bags or pharmacy compounding protocols. Commercial value increases when the product reduces:

• Pharmacy preparation time.
• Manipulation steps.
• Dosing errors.
• Product waste.
• Cold-chain complexity.
• Training requirements.

The product itself may remain unchanged while packaging, labeling, and workflow integration create differentiation.

Pediatric and neonatal nutrition

Pediatric and neonatal use requires tighter control of dose, infusion rate, lipid exposure, and physical compatibility. Commercial opportunities include:

• Smaller-volume presentations.
• Dose-calibrated delivery systems.
• Low-surface-area containers.
• Improved light and oxygen protection.
• Data on admixture stability.
• Pharmacy-friendly pediatric packaging.

Neonatal products require particularly strong evidence because immature hepatic function, low body weight, and high sensitivity to particulate and dosing errors raise the clinical and regulatory stakes.

Regional manufacturing and licensing

A local manufacturer could pursue licensing or contract manufacturing based on:

• Access to sterile emulsion production.
• Regional soybean-oil sourcing.
• Local phospholipid supply.
• Government hospital tenders.
• Reduced import dependence.
• Backup manufacturing for shortage mitigation.

The most valuable licensing package would include validated homogenization parameters, raw-material specifications, container-closure data, stability protocols, and regulatory filings. A mere trademark or distribution license would be less defensible than a manufacturing and quality package.

Which companies compete with NUTRILIPID?

The competitive landscape includes Fresenius Kabi, Baxter, and other suppliers of parenteral nutrition products. Competition is divided between soybean-oil emulsions and newer mixed-oil or fish-oil products.

Competitive axis	NUTRILIPID position	Competitive pressure
Product maturity	Strong	Mature products face price competition
Soybean-oil supply	Established	Agricultural and geopolitical variability
Clinical familiarity	Strong	Mixed-oil products can differentiate through lipid composition
Hospital purchasing	Strong where contracted	Competitors can enter through shortages or tender pricing
Pediatric use	Established	Specialty products may offer targeted positioning
Formulation innovation	Limited relative to mixed-oil products	New emulsifier and oil systems can shift share
Manufacturing complexity	High	Limits the number of credible entrants

NUTRILIPID competes on reliability and familiarity. SMOFlipid, Clinolipid, and Omegaven compete through lipid composition and disease-specific positioning rather than direct price parity alone.

What patent litigation and Paragraph IV risks affect NUTRILIPID?

No major, widely reported Paragraph IV litigation should be treated as the central current risk without confirmation from the relevant FDA, PACER, and patent records. For a mature injectable emulsion, litigation exposure is more likely to arise from:

• Formulation patents on alternative lipid systems.
• Manufacturing patents covering homogenization or sterilization.
• Container technologies.
• Admixture compatibility claims.
• Method-of-use claims for specialized patient populations.
• Trade-secret disputes involving process parameters.

A Paragraph IV challenge would be commercially meaningful only if a listed patent remained active and covered the proposed ANDA product. The absence of a prominent patent dispute does not eliminate freedom-to-operate risk because unlisted patents, process patents, foreign patents, and contractual restrictions may still affect manufacturing or commercialization.

How strong is the NUTRILIPID patent estate?

The product’s practical defensibility appears stronger in manufacturing execution, quality systems, regulatory history, and hospital supply relationships than in a single blocking composition patent.

Patent-estate factor	Assessment
Composition patent leverage	Limited for a mature soybean-oil formulation unless active claims are identified
Process protection	Potentially meaningful
Packaging protection	Potentially meaningful
Method-of-use protection	More relevant for differentiated clinical indications
Regulatory know-how	High practical value
Supply-chain qualification	High commercial value
Brand and contracting	High in hospital channels
Biosimilar protection	Not applicable because NUTRILIPID is not a biologic

The principal opportunity for new intellectual property is a differentiated formulation with measurable performance advantages, such as improved oxidative stability, controlled droplet-size distribution, reduced allergen burden, or superior compatibility with all-in-one parenteral nutrition systems.

What is the FDA regulatory status of NUTRILIPID?

NUTRILIPID is an FDA-approved prescription intravenous fat emulsion. FDA labeling identifies its use as a source of calories and essential fatty acids in parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated.[1]

Regulatory diligence should address:

• Current NDA and supplement history.
• Approved strengths and presentations.
• Current prescribing information.
• Manufacturing sites.
• Product-specific supplements.
• Current shortage or supply notices.
• Orange Book patent and exclusivity entries.
• Postmarketing safety information.
• Labeling related to egg and soybean hypersensitivity.

Because this is a sterile injectable emulsion, FDA scrutiny centers on formulation control, sterility, particulate matter, manufacturing consistency, and container performance.

What revenue exposure does NUTRILIPID create?

Fresenius Kabi does not generally report NUTRILIPID revenue as a separately disclosed public product line. Revenue exposure must therefore be estimated from institutional volume, tender pricing, bag size, product mix, and parenteral-nutrition market share rather than company-level financial statements.

The product’s economic value is linked to recurring hospital consumption. Demand is supported by:

• Intensive-care admissions.
• Major surgery.
• Oncology treatment.
• Gastrointestinal failure.
• Neonatal and pediatric care.
• Home parenteral nutrition.
• Hospital shortages of competing lipid emulsions.

Price erosion risk is highest when multiple suppliers qualify equivalent soybean-oil emulsions. Supply shortages can temporarily increase the value of manufacturing capacity and create switching opportunities for competitors.

Key Takeaways

• NUTRILIPID is a mature soybean-oil intravenous lipid emulsion manufactured by Fresenius Kabi.
• Its key excipients are egg phospholipids, glycerin, sodium hydroxide, and water for injection.
• Egg phospholipids are the most strategically important excipient because they control emulsion stability and create allergen and sourcing considerations.
• The strongest formulation opportunities involve oxidation control, alternative phospholipids, mixed-oil systems, and improved packaging.
• Generic competition is constrained by injectable-emulsion equivalence, sterile manufacturing, particle-size control, and hospital contracting.
• The product is not a biologic, so biosimilar competition is not applicable.
• NUTRILIPID revenue is not separately disclosed by Fresenius Kabi.
• The most defensible commercial advantages are supply reliability, manufacturing know-how, regulatory history, compounding compatibility, and institutional contracts.
• Current Orange Book listings, patent families, and litigation records must be evaluated by application number and product presentation before making a launch or freedom-to-operate decision.

FAQs

Can egg phospholipids in NUTRILIPID be replaced with synthetic phospholipids?

Yes, technically, but the change would require extensive comparative characterization and regulatory support. The replacement must preserve droplet-size distribution, stability, sterility, compatibility, and clinical performance.

Is NUTRILIPID interchangeable with SMOFlipid?

No. The products have different lipid compositions and labeling. Formulary substitution depends on the clinical indication, institutional policy, prescriber authorization, and applicable regulatory requirements.

Does NUTRILIPID contain preservatives?

The product is formulated as a sterile intravenous emulsion and is not positioned as a preserved multidose product. The current package insert should be used to confirm the excipient and container presentation for each marketed size.[1]

Can NUTRILIPID be mixed with total parenteral nutrition?

It may be used as part of parenteral nutrition under validated pharmacy procedures. Compatibility depends on the amino acid, dextrose, electrolyte, trace-element, vitamin, and container system used.

What is the most attractive commercial improvement to NUTRILIPID?

Improved oxygen and light protection combined with validated admixture stability is likely to offer the clearest near-term value. A new mixed-oil or synthetic-phospholipid product offers greater differentiation but requires substantially more regulatory and clinical investment.

References

1. DailyMed. (n.d.). NUTRILIPID I.V. Fat Emulsion prescribing information. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. DailyMed. (n.d.). Intralipid prescribing information. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/

4. DailyMed. (n.d.). SMOFlipid prescribing information. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/

5. DailyMed. (n.d.). Clinolipid prescribing information. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/

6. DailyMed. (n.d.). Omegaven prescribing information. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/